Physician preferences for extra-glycemic effects of type 2 diabetes treatments

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 443-459

  Poulos, Christine ^a   González, Juan Marcos ^a   Lee, Lauren J ^b,c   Boye, Kristin S ^b   Johnson, F Reed ^a   Bae, Jay P ^b   Deeg, Mark A ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

Conjoint analysis; Diabetes treatments; Discrete choice experiment survey; Extra glycemic effects; Glycemic control; Patient preferences; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C;

ARTICLE; DEPRESSION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEALTH SURVEY; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; QUESTIONNAIRE; SEDENTARY LIFESTYLE; WEIGHT CHANGE;

EID: 84899854035     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0046-7     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011; 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (Accessed Dec 13, 2012).
2. Diabetes UK. Diabetes in the UK 2012: key statistics on diabetes; 2012. e-linkurl http://www.diabetes.org.uk//url/e-linkDocuments/Reports/Diabetes-in-the-UK-2012.pdf (Accessed Dec 13, 2012).
3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596-615.
4. Kanavos P, van den Aardweg S, Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries; 2012. e-linkurl http://www2.lse.ac.uk//url/e-linkLSEHealthAndSocialCare/research/LSEHealth/MTRG/LSEDiabetesReport26Jan2012.pdf (Accessed Dec 13, 2012).
5. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2009;33(Suppl. 1):S11-61.
6. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167:1145-51.
7. Lloyd C. The effects of diabetes on depression and depression on diabetes. Diabetes Voice. 2008;53: 23-6.
8. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complicat. 2005;19: 113-22.
9. Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635-43.
10. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood). 2003;Suppl Web Exclusives:W3219-W3226.
11. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734-43.
12. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42:200-9.
13. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836-41.
14. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27:2800-5.
15. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65:314-22.
16. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-72.
17. Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403-13.
18. Marshall D, Bridges JF, Hauber B, et al. Conjoint analysis applications in health-how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient. 2010;3:249-56.
19. Hauber AB, Johnson FR, Sauriol L, Lescrauwaet B. Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care. 2005;28:2243-5.
20. Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucoselowering agents. Diabet Med. 2009;26:416-24.
21. Johnson FR, Hauber B, Ozdemir S, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm. 2010;16:616-28.
22. Poulos C, Yang JC, Levin C, Van Minh H, Giang K, Nguyen D. Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Soc Sci Med. 2011;73:226-34.
23. Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. New York: Cambridge University Press; 2000.
24. Akl EA, Oxman AD, Herrin J, et al. Using alternative statistical formats for presenting risks and risk reductions. Cochrane Database Syst Rev. 2011;16:CD006776.
25. Dey A. Orthogonal fractional factorial designs. New York: Halstead Press; 1985.
26. Kanninen B. Optimal design for multinomial choice experiments. J Mark Res. 2002;39:214-27.
27. Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discretechoice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16:3-13.
28. Bech M, Kjaer T, Lauridsen J. Does the number of choice sets matter? Results from a web survey applying a discrete choice experiment. Health Econ. 2011;20:273-86.
29. Swait J, Adamowicz W. The influence of task complexity on consumer choice: a latent class model of decision strategy switching. J Consum Res. 2001;28:135-48.
30. Johnson FR, Yang J-C, Mohamed AF. In Defense of imperfect experimental designs: statistical efficiency and measurement error in choice-format conjoint analysis. Podium presentation at the 4th conjoint analysis in health conference, Orlando; 2012.
31. Porzsolt F, Clouth J, Deutschmann M, Hippler HJ. Preferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care values. Health Qual Life Outcomes. 2010;8:125.
32. Matza LS, Yurgin N, Boye KS, Malley K, Shorr JM. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Curr Med Res Opin. 2007;23: 2051-62.
33. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35 Suppl. 1:S11-63.
34. National Institute for Health and Care Excellence (NICE). Diabetes in Adults. Quality Standards QS6. 2013. e-linkurl http://www.nice.org.uk/guidance/QS6/url/e-link (Accessed 30 Aug, 2013).
35. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and precancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. e-linkurl http://www.fda/url./e-linkgov/drugs/drugsafety/ucm343187.htm (Accessed 30 Aug, 2013).
36. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013;36:2126-32.
37. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care. 2013;36:2118-25.